| 000 | 01595 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517190435.0 | ||
| 264 | 0 | _c20171226 | |
| 008 | 201712s 0 0 eng d | ||
| 022 | _a1471-2415 | ||
| 024 | 7 |
_a10.1186/s12886-017-0617-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aReich, Oliver | |
| 245 | 0 | 0 |
_aInjections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland. _h[electronic resource] |
| 260 |
_bBMC ophthalmology _cDec 2017 |
||
| 300 |
_a234 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHealth Care Costs _xstatistics & numerical data |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIntravitreal Injections _xeconomics |
| 650 | 0 | 4 |
_aMacular Degeneration _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aRanibizumab _xadministration & dosage |
| 650 | 0 | 4 |
_aReceptors, Vascular Endothelial Growth Factor _xadministration & dosage |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xadministration & dosage |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSwitzerland |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aSchmid, Martin K | |
| 700 | 1 | _aRapold, Roland | |
| 700 | 1 | _aBachmann, Lucas M | |
| 700 | 1 | _aBlozik, Eva | |
| 773 | 0 |
_tBMC ophthalmology _gvol. 17 _gno. 1 _gp. 234 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12886-017-0617-x _zAvailable from publisher's website |
| 999 |
_c27851957 _d27851957 |
||